A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 05 Feb 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results assessing Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 18 Sep 2019 Planned End Date changed from 1 Feb 2024 to 1 Jan 2021.